Table 2.
Patients with first on-study skeletal-related events by type
| Zoledronic acid (n=951) |
Denosumab (n=950) |
|
|---|---|---|
| Total confirmed events | 386 (41%) | 341 (36%) |
| Radiation to bone | 203 (21%) | 177 (19%) |
| Pathological fracture | 143 (15%) | 137 (14%) |
| Spinal cord compression | 36 (4%) | 26 (3%) |
| Surgery to bone | 4 (<1%) | 1 (<1%) |
Data are number (%).